MedTrace Logo

Transplantation of Autologous Olfactory Ensheathing Cells in Complete Human Spinal Cord Injury

NCT01231893 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2010-11-01

No results posted yet for this study

Summary

The purpose of this experimental therapy is an assessment of the safety and feasibility of transplantation of autologous olfactory ensheathing glia and olfactory fibroblasts obtained from the olfactory mucosa in patients with complete spinal cord injury.

Conditions

  • Complete Spinal Cord Injuries

Interventions

PROCEDURE

olfactory mucosa ensheathing cell grafting, rehabilitation

In this group patients are planned to underwent a biopsy of their own olfactory mucosa for isolation and culture of olfactory ensheathing cells and olfactory fibroblasts. The suspension of these cells will be next transplanted into the focus of spinal cord injury. Before and after surgery the patients will undergo an intense neurorehabilitation program.

OTHER

rehabilitation

In this group the patients will not undergo any surgical procedure. They will participate in the same rehabilitation protocol that is planned for the patients from the experimental group.

Sponsors & Collaborators

  • Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences

    collaborator OTHER

  • Department of Rehabilitation in Spinal Cord Injuries Akson

    collaborator UNKNOWN

  • Wroclaw Medical University

    lead OTHER

Principal Investigators

  • Wlodzimierz Jarmundowicz, M.D. Ph.D. · Department of Neurosurgery of Wroclaw Medical University

  • Pawel Tabakow, M.D. Ph.D. · Department of Neurosurgery of Wroclaw Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01231893 on ClinicalTrials.gov